Gene therapy for wet AMD: could this mean fewer eye injections?

NCT ID NCT04645212

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study follows 23 people with wet age-related macular degeneration who received a single dose of ADVM-022 gene therapy in an earlier trial. Researchers are checking how safe the treatment is over time and whether it continues to control the disease, potentially reducing the need for regular eye injections. The goal is to see if this one-time gene therapy can keep vision stable with less ongoing treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

blindness (disorder) choroidal neovascularization eye disorder macular degeneration retinal degeneration retinal disorder wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Adverum Clinical Site

    Bakersfield, California, 93309, United States

  • Adverum Clinical Site

    Beverly Hills, California, 90211, United States

  • Adverum Clinical Site

    Lakewood, Colorado, 80228, United States

  • Adverum Clinical Site

    Deerfield Beach, Florida, 33064, United States

  • Adverum Clinical Site

    Reno, Nevada, 89502, United States

  • Adverum Clinical Site

    Philadelphia, Pennsylvania, 19107, United States

  • Adverum Clinical Site

    Nashville, Tennessee, 37203, United States

  • Adverum Clinical Site

    Bellaire, Texas, 77401, United States

  • Adverum Clinical Site

    The Woodlands, Texas, 77384, United States